Rita Norvilaite1, Akvile Kablyte1, Dr. Gediminas Raila2
1Lithuanian University of HealthSciences, A. Mickevičiaus str. 9, LT-44307 Kaunas, Lithuania
2Family medicine clinic, Hospitalof Lithuanian university of Health sciences, Eiveniu str. 2, LT-50009 Kaunas, Lithuania
Anthracycline (doxorubicin, epirubicin, daunorubicin, idarubicin) chemotherapy is one of the most common type of solid tumors and haematological malignancies treatment more than three decades. Heart muscle damage, left ventricular dysfunction and congestive heart failure are the most life threatening side effects of anthracyclines cardiotoxity. The purpose of this article is to review monitoring and prevention possibilities of cardiovascular complications in patients with anthracycline chemotherapy.
Keywords: cardiotoxity, anthracyclines, chemotherapy, prevention.